Pale Fire Capital Se Uni Qure N.V. Transaction History

Pale Fire Capital Se

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$8.34 - $17.27 $562,441 - $1.16 Million	67,439 Added 14.59%	529,798 $7.39 Billion
Q1 2025 May 14, 2025	SELL	$10.6 - $18.08 $1.25 Million - $2.14 Million	-118,349 Reduced 20.38%	462,359 $4.9 Billion
Q4 2024 Feb 13, 2025	BUY	$4.54 - $17.73 $1.11 Million - $4.33 Million	244,240 Added 72.59%	580,708 $10.3 Billion
Q3 2024 Nov 12, 2024	BUY	$3.78 - $10.12 $1.02 Million - $2.74 Million	270,868 Added 412.91%	336,468 $1.66 Billion
Q4 2023 Feb 13, 2024	BUY	$5.63 - $8.27 $30,965 - $45,485	5,500 Added 9.15%	65,600 $444 Million

Q2 2023 Aug 11, 2023	BUY	$11.12 - $22.2 $668,312 - $1.33 Million	60,100 New	60,100 $689 Million

265

51M

3.92M

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $1.4B
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Pale Fire Capital Se, based on Form 13F filings with the SEC.

Stay updated on Pale Fire Capital Se with notifications on news.